Azerbaijan provides advanced systemic therapies for esophageal cancer, including immunotherapy, targeted drugs, and integrative oncothermia. JCI-accredited centers in Baku administer Pembrolizumab and Nivolumab following international protocols. Specialized treatments also include Trastuzumab for HER2+ cases and high-dose vitamin C protocols for complication management.
- Systemic immunotherapy: Pembrolizumab and Nivolumab are available for advanced or metastatic esophageal squamous cell carcinoma.
- Targeted biological therapy: Trastuzumab and Ramucirumab target specific biomarkers like HER2 and vascular endothelial growth.
- Integrative oncothermia: Advanced hyperthermia therapy (oncothermia) is used alongside chemotherapy to enhance tumor response.
- Standard chemotherapy: Regimens include platinum agents, fluoropyrimidines, and taxanes for neoadjuvant or metastatic care.
Bookimed Expert Insight: Baku has emerged as a regional hub for integrative oncology. While traditional hospitals focus on chemotherapy, clinics like Biological Medicine - Integrative Health Center combine German-trained expertise with local accessibility. Data shows these centers specialize in treating chemotherapy complications using mistletoe therapy and high-dose vitamin C, which is rare in standard clinical settings.
Patient Consensus: Patients emphasize that biomarker testing is essential for accessing targeted drugs and immunotherapy. Many recommend seeking treatment at large cancer centers in Baku to ensure access to multidisciplinary teams and modern molecular diagnostics.